BNP Paribas Arbitrage SA lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 40.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,803 shares of the company’s stock after selling 14,412 shares during the period. BNP Paribas Arbitrage SA’s holdings in Thermo Fisher Scientific were worth $3,309,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Bank of Montreal Can bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $32,053,000. Carmignac Gestion raised its position in Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock valued at $597,918,000 after buying an additional 763,421 shares during the period. Evercore Wealth Management LLC raised its position in Thermo Fisher Scientific by 6.0% in the second quarter. Evercore Wealth Management LLC now owns 281,316 shares of the company’s stock valued at $41,568,000 after buying an additional 15,849 shares during the period. First Pacific Advisors LLC raised its position in Thermo Fisher Scientific by 5.9% in the second quarter. First Pacific Advisors LLC now owns 1,788,830 shares of the company’s stock valued at $264,318,000 after buying an additional 99,770 shares during the period. Finally, Columbus Circle Investors raised its position in Thermo Fisher Scientific by 363.2% in the second quarter. Columbus Circle Investors now owns 668,109 shares of the company’s stock valued at $98,720,000 after buying an additional 523,867 shares during the period. 86.28% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.68% during mid-day trading on Tuesday, hitting $141.27. The stock had a trading volume of 2,576,593 shares. The company has a market cap of $55.81 billion, a P/E ratio of 28.24 and a beta of 1.24. The company has a 50-day moving average price of $149.29 and a 200 day moving average price of $151.92. Thermo Fisher Scientific Inc. has a 1-year low of $119.75 and a 1-year high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, October 27th. The company reported $2.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.97 by $0.06. The company earned $4.49 billion during the quarter, compared to analyst estimates of $4.39 billion. Thermo Fisher Scientific had a net margin of 11.10% and a return on equity of 14.95%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the business posted $1.80 earnings per share. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post $8.25 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Investors of record on Thursday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Tuesday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 12.00%.

ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this story can be accessed at http://www.dailypolitical.com/2016/11/29/thermo-fisher-scientific-inc-tmo-position-decreased-by-bnp-paribas-arbitrage-sa.html.

A number of equities analysts recently issued reports on the company. Bank of America Corp. set a $180.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Friday, October 7th. Cleveland Research lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Friday, September 9th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $172.00 price objective for the company in a report on Thursday, October 13th. JPMorgan Chase & Co. assumed coverage on Thermo Fisher Scientific in a report on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 price objective for the company. Finally, Leerink Swann reissued a “buy” rating and issued a $175.00 price objective on shares of Thermo Fisher Scientific in a report on Sunday, November 20th. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $164.37.

In related news, CEO Marc N. Casper sold 28,797 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the completion of the sale, the chief executive officer now owns 307,444 shares of the company’s stock, valued at $46,427,118.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $151.17, for a total transaction of $4,535,100.00. Following the completion of the sale, the chief executive officer now directly owns 308,647 shares of the company’s stock, valued at approximately $46,658,166.99. The disclosure for this sale can be found here. 0.52% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.